Agenus announces promising trial results for colon cancer treatment at ESMO Congress
Agenus Inc. (Nasdaq: AGEN), a pioneer in the development of immunological agents for cancer treatment, has recently unveiled promising results from an investigator-sponsored trial (IST) of its novel therapies, botensilimab and balstilimab (BOT/BAL), for treating colon cancer. These findings were presented at the 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, […]